Combined inhibition of CDK4/6 and PI3K pathways exhibit highly synergistic activity and translational potential in Ewing sarcoma
Open Access
- 18 June 2026
- journal article
- Published by Elsevier in Translational Oncology
- Vol. 71, 102866
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- National Center for Advancing Translational Sciences
- Bayer Diabetes Care
- Pediatric Cancer Research Foundation
- Rally Foundation
This publication has 50 references indexed in Scilit:
- Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcomaCancer Medicine, 2023
- Inhibition of the PI3K/AKT/mTOR signaling promotes an M1 macrophage switch by repressing the ATF3-CXCL8 axis in Ewing sarcomaCancer Letters, 2022
- TK216 targets microtubules in Ewing sarcoma cellsCell Chemical Biology, 2022
- Targeting the IGF/PI3K/mTOR pathway and AXL/YAP1/TAZ pathways in primary bone cancerJournal of Bone Oncology, 2022
- Reverse Phase Protein Arrays2020
- Comprehensive Analysis of Hypermutation in Human CancerCell, 2017
- Longitudinal follow‐up of adult survivors of Ewing sarcoma: A report from the Childhood Cancer Survivor StudyCancer, 2017
- CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K InhibitorsCancer Cell, 2014
- Risk of recurrence and survival after relapse in patients with Ewing sarcomaPediatric Blood & Cancer, 2011
- Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi‐modality therapy: A report from the Children's Oncology GroupPediatric Blood & Cancer, 2008